OBJECTIVES: The aim of this study is to estimate, in Chile, the clinical and budget impact of cervical cancer primary screening with a HPV-16/18 genotyping test which simultaneously detects 12 other high-risk HPV types. METHODS: A decision tree framework was used to model the screening and diagnosis of cervical cancer to compare three strategies: (1) Cytology alone – Screening Interval (SI): 3 years; (2) Pooled HPV with reflex cytology – SI: 5 years; (3) HPV with 16/18 genotyping and reflex cytology (cobas® 4800) – SI: 5 years, from a payer’s perspective.  The impact model was run by having the women cohort progress through the model with 2 screening cycles. In addition, the screening and cancer treatment costs were calculated from FONASA public data (Fondo Nacional de Salud) reported in 2014 converted to US dollars (USD).  RESULTS: The Budget Impact Model indicates that, when comparing the Strategy 2 and 3 to Strategy 1 there is an increase of ≥CIN2 (Cervical Intraepithelial Neoplasia)  cases detected, treated and a reduction at the number of patients progressing to cervical cancer. When comparing the strategy 2 to strategy 1, the model estimated savings of 1.9% at the annual costs, including screening, diagnosis and treatment. There is also a decrease of 25% and 33% at the incidence of Cervical Cancer and Mortality Rate, respectively. Better clinical results could be achieved when the strategy 3 is implemented. An additional investment of only 0.37% at the annual budget would be necessary to decrease the incidence of Cervical Cancer by 43% and the mortality rate by 54% in Chile. CONCLUSIONS: This analysis suggests that the use of the HPV genotyping test (strategy 3) is a potential effective management strategy, given that the clinical impacts are highly positives and budgetary impact is basically neutral, comparing to the current screening program in Chile.